22:53 , Jul 23, 2019 |  BC Extra  |  Clinical News

July 23 Clinical Quick Takes: Achillion plans U.S. IND; plus Chiasma, Myovant, Marinus and Merck

Achillion plans U.S. IND after latest readout for ACH-5228  Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) rose $1.19 (50%) to $3.57 since announcing early Monday that multiple ascending doses of its CFD inhibitor ACH-5228 led to 95% complement...
21:51 , Mar 7, 2019 |  BC Extra  |  Financial News

Follow-on roundup: Horizon, Apellis, Epizyme

Horizon, Apellis and Epizyme each priced follow-ons raising a total of $552 million. Horizon Pharma plc (NASDAQ:HZNP) raised $300 million late Wednesday through the sale of 12 million shares at $24.50. The price is a...
01:35 , Mar 1, 2019 |  BC Week In Review  |  Clinical News

Horizon Phase III teprotumumab data tee up BLA

Horizon Pharma plc (NASDAQ:HZNP) said teprotumumab (HZN-001) met the primary and all secondary endpoints in the Phase III OPTIC trial to treat Graves orbitopathy, also known as thyroid eye disease. The company plans to submit...
19:46 , Feb 28, 2019 |  BC Extra  |  Clinical News

Horizon jumps after teprotumumab data tee up BLA

Horizon Pharma plc (NASDAQ:HZNP) added $7.16 (33%) $29.01 on Thursday after reporting that teprotumumab (HZN-001) met the primary and all secondary endpoints in the Phase III OPTIC trial to treat Graves orbitopathy, also known as...
23:42 , Jan 3, 2019 |  BC Innovations  |  Targets & Mechanisms

Getting kumbaya with infections

Up-and-comer Janelle Ayres is flipping the script on antibiotic resistance with a strategy to convert bacteria from virulent pathogens into benign members of the microbiome and turn infectious diseases into harmless conditions. The idea is...
19:28 , Sep 10, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Patient-derived oligocortical spheroids could be used to study demyelinating diseases and screen therapies to treat them. The spheroids were generated by culturing human pluripotent stem cells with platelet derived growth factor AA...
21:49 , Aug 29, 2018 |  BC Extra  |  Preclinical News

Sequential therapies trigger axon regeneration in spinal cord injury

University of California Los Angeles and Swiss Federal Institute of Technology Lausanne (EPFL) researchers showed delivery of three sequential therapies could trigger axon growth after complete spinal cord injury in rodents, suggesting the combination approach...
01:46 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

Unsaturated remyelination

Enzymes downstream in cholesterol biosynthesis could provide new ways to stimulate remyelination that avoid the baggage of previously identified multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo...
21:40 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Sarcoma Cell culture and mouse studies suggest combining Mekinist trametinib with IGF1R inhibitors could help treat PAX3-PAX7 fusion-negative rhabdomyosarcoma. Screening of a panel of 1,912 approved or tool compound small molecule inhibitors in a...
21:38 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Small cell lung cancer Patient sample and cell culture studies suggest promoting IGFBP5 expression or inhibiting POU2F3 or IGF1R could help treat POU2F3-expressing small cell lung cancer (SCLC). In tumor samples from SCLC patients,...